文献速递心力衰竭与心肌病心律失常

乳头肌瘢痕在扩张型心肌病中的预后价值

Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2025-01-01

本研究在470例扩张型心肌病患者中,采用血流非依赖性暗血延迟增强心脏磁共振检测乳头肌瘢痕,发现29.1%的患者存在乳头肌瘢痕,且其与心脏死亡、心力衰竭事件及心律失常事件独立相关。

要点

  • 乳头肌瘢痕在扩张型心肌病患者中检出率约29.1%,与左心室射血分数无关。
  • 乳头肌瘢痕独立增加心脏死亡风险(HR 1.86),并提供增量预后价值。
  • 乳头肌瘢痕亦独立增加心衰事件(HR 2.05)和心律失常事件(HR 3.41)风险。

核心结论

  • 乳头肌瘢痕在扩张型心肌病患者中约占三分之一,且独立与心脏死亡相关。

主要发现

  • 中位随访至8年(共2082患者年),发生53例心脏死亡、49例心衰事件和24例心律失常事件。

关键数值与推荐

  • 乳头肌瘢痕定义为暗血延迟增强心脏磁共振检测到的乳头肌延迟强化。
  • 主要终点为心脏死亡;次要终点包括心衰事件复合终点(心衰死亡或心脏移植)和心律失常事件复合终点(心脏性猝死或复苏成功的心脏性猝死)。

临床怎么用

  • 在扩张型心肌病患者中,可通过暗血延迟增强心脏磁共振检测乳头肌瘢痕以辅助风险分层。
  • 乳头肌瘢痕的存在提示心脏死亡、心衰及心律失常风险增高,可考虑加强监测与随访。

局限性

  • 单中心队列研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Papillary muscle scarring (papSCAR) can occur without epicardial coronary artery disease, likely due to microvascular dysfunction. Dilated cardiomyopathy (DCM) has been associated with microvascular dysfunction; the prevalence and prognostic significance of papSCAR in patients with DCM are unclear. OBJECTIVE: To determine the prevalence of papSCAR in patients with DCM and to evaluate if papSCAR is associated with adverse outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted among consecutive patients with known or suspected DCM prospectively enrolled at an academic hospital in North Carolina from January 2011 to December 2020. Patients were referred for cardiovascular magnetic resonance (CMR) imaging, and the study protocol included flow-independent dark blood delayed-enhancement (FIDDLE) imaging, which improves the detection of papSCAR. Data were analyzed from January 2022 to December 2022. MAIN OUTCOMES AND MEASURES: The primary end point was cardiac mortality. Secondary end points included a composite of heart failure events (heart failure death or cardiac transplant) and a composite of arrhythmia events (sudden cardiac death [SCD] or aborted SCD). RESULTS: This cohort study included 470 patients (mean [SD] age, 55.3 [14.3] years; 205 female patients [43.6%]). During up to 8 years of follow-up (2082 patient-years), there were 53 cardiac deaths, 49 heart failure events, and 24 arrhythmia events. PapSCAR was present in 137 patients (29.1%), and mean (SD) left ventricular ejection fraction (LVEF) was similar between those with and without papSCAR (30.7% [11.0%] vs 31.4% [10.3%]; P = .52). Patients with papSCAR had a higher rate of cardiac death than those without (19.0% vs 8.1%; hazard ratio [HR], 2.30; 95% CI, 1.34-3.95; P = .002). After adjustment for prespecified variables known to have prognostic value in DCM (age, systolic blood pressure, heart rate, LVEF, and midwall myocardial scar), papSCAR was independently associated with cardiac death (HR, 1.86; 95% CI, 1.07-3.24; P = .03) and provided incremental prognostic value (incremental χ2, 4.68; P = .03). PapSCAR was also independently associated with heart failure events (HR, 2.05; 95% CI, 1.16-3.61; P = .01) and arrhythmia events (HR, 3.41; 95% CI, 1.46-7.94; P = .005). CONCLUSIONS AND RELEVANCE: In this single-center cohort study, papSCAR as detected by dark blood delayed-enhancement CMR was present in approximately one-third of patients with DCM and was independently associated with cardiac death.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kaolawanich Y, Wendell DC, Kim HW, et al. Prognostic Value of Papillary Muscle Scarring in Patients With Dilated Cardiomyopathy. JAMA Cardiol. 2025. PMID: 41091460. doi:10.1001/jamacardio.2025.3822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。